Dr Rick Doblin - The Latest Developments in MAPS' Research

MAPS utilizes scientific and medical pathways to bridge the gap between niche psychedelic exploration and mainstream clinical acceptance. Currently leading MDMA-assisted psychotherapy research for treatment-resistant PTSD, the organization employs public benefit corporations to bridge the mission-driven non-profit model with essential revenue generation needed for sustainable pharmaceutical development. Broad goals include formalizing therapist training and establishing standardized clinical settings. Strategic collaborations with governmental entities like the Veterans Affairs department further validate these treatments. Emerging data emphasizes the clinical viability of MDMA, while harm reduction initiatives like the Zendo Project demonstrate safer, community-based integration strategies at festivals. These efforts collectively work toward reclassifying psychedelics from stigmatized counter-culture objects into regulated, evidence-based tools for global health and spirituality.